Blueprint Medicines Co. (NASDAQ:BPMC) Shares Sold by Bank of Montreal Can

Bank of Montreal Can decreased its holdings in shares of Blueprint Medicines Co. (NASDAQ:BPMC) by 0.7% during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 68,562 shares of the biotechnology company’s stock after selling 478 shares during the quarter. Bank of Montreal Can owned about 0.11% of Blueprint Medicines worth $6,345,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors have also recently added to or reduced their stakes in the company. Comerica Bank boosted its stake in shares of Blueprint Medicines by 2,582.9% in the first quarter. Comerica Bank now owns 10,839 shares of the biotechnology company’s stock valued at $1,028,000 after purchasing an additional 10,435 shares during the period. DekaBank Deutsche Girozentrale grew its stake in shares of Blueprint Medicines by 2.9% during the first quarter. DekaBank Deutsche Girozentrale now owns 25,883 shares of the biotechnology company’s stock valued at $2,531,000 after acquiring an additional 733 shares in the last quarter. CWM LLC increased its position in shares of Blueprint Medicines by 114.6% during the second quarter. CWM LLC now owns 1,105 shares of the biotechnology company’s stock worth $119,000 after acquiring an additional 590 shares during the last quarter. SG Americas Securities LLC lifted its stake in shares of Blueprint Medicines by 82.8% in the second quarter. SG Americas Securities LLC now owns 21,684 shares of the biotechnology company’s stock worth $2,337,000 after acquiring an additional 9,819 shares in the last quarter. Finally, Diversified Trust Co boosted its holdings in Blueprint Medicines by 9.9% in the second quarter. Diversified Trust Co now owns 15,910 shares of the biotechnology company’s stock valued at $1,715,000 after purchasing an additional 1,438 shares during the last quarter.

Analysts Set New Price Targets

A number of equities analysts have issued reports on BPMC shares. UBS Group initiated coverage on Blueprint Medicines in a research report on Thursday, October 24th. They issued a “neutral” rating and a $88.00 target price on the stock. JMP Securities reaffirmed a “market outperform” rating and issued a $125.00 price target on shares of Blueprint Medicines in a report on Monday, November 18th. Needham & Company LLC reissued a “buy” rating and set a $135.00 price objective on shares of Blueprint Medicines in a report on Friday, November 15th. HC Wainwright restated a “buy” rating and issued a $135.00 target price on shares of Blueprint Medicines in a research note on Friday, November 15th. Finally, JPMorgan Chase & Co. began coverage on Blueprint Medicines in a research note on Thursday, November 14th. They issued an “overweight” rating and a $126.00 price target for the company. One equities research analyst has rated the stock with a sell rating, seven have assigned a hold rating, twelve have assigned a buy rating and two have assigned a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $122.11.

Insider Buying and Selling

In related news, COO Christina Rossi sold 2,274 shares of Blueprint Medicines stock in a transaction that occurred on Wednesday, November 27th. The shares were sold at an average price of $95.10, for a total value of $216,257.40. Following the transaction, the chief operating officer now directly owns 71,657 shares of the company’s stock, valued at $6,814,580.70. This trade represents a 3.08 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, insider Fouad Namouni sold 3,633 shares of the firm’s stock in a transaction on Thursday, October 3rd. The shares were sold at an average price of $89.32, for a total value of $324,499.56. Following the completion of the sale, the insider now directly owns 69,070 shares in the company, valued at approximately $6,169,332.40. This represents a 5.00 % decrease in their position. The disclosure for this sale can be found here. 4.21% of the stock is currently owned by insiders.

Blueprint Medicines Price Performance

BPMC stock opened at $97.62 on Tuesday. The stock has a market cap of $6.20 billion, a PE ratio of -45.68 and a beta of 0.59. The stock has a 50-day moving average price of $90.97 and a two-hundred day moving average price of $98.04. Blueprint Medicines Co. has a 1 year low of $70.39 and a 1 year high of $121.90. The company has a current ratio of 3.32, a quick ratio of 3.27 and a debt-to-equity ratio of 1.09.

Blueprint Medicines (NASDAQ:BPMC) last announced its quarterly earnings data on Wednesday, October 30th. The biotechnology company reported ($0.89) EPS for the quarter, topping analysts’ consensus estimates of ($0.97) by $0.08. Blueprint Medicines had a negative net margin of 29.48% and a negative return on equity of 112.30%. The business had revenue of $128.20 million for the quarter, compared to analyst estimates of $127.56 million. During the same quarter in the previous year, the firm posted ($2.20) earnings per share. The firm’s revenue for the quarter was up 126.5% on a year-over-year basis. Equities analysts forecast that Blueprint Medicines Co. will post -3.68 EPS for the current fiscal year.

About Blueprint Medicines

Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM, and other mast cell disorders.